Pfizer bets big on a bispecific
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
Takeda says no to B7-H3
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
Vepdegestrant’s promise narrows
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
AUA 2025 – Pfizer catches the Crest of a subQ wave
But sasanlimab's use looks set to remain narrow.
Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
Sutro calls time on folate
At long last luvelta-T is shelved, and Sutro seeks a new focus.
Arvinas’s degrader disappoints
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
GSK and Hansoh press on despite Pfizer’s exit
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
